Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The biopharmaceutical company said European sales revenue rose to EUR 9.0 million in the first half of 2026 and EBITDA from continuing operations improved to EUR 1.7 million. It also reported record Ameluz unit sales in Germany and higher cash of EUR 7.1 million.
Biofrontera AGby Investor RelationsBusiness news for the stock marketBiofrontera AG: Biofrontera reports results for the first half of 2026Leverkusen (pta000/30.09.2026/13:30 UTC+2)Leverkusen, September 30, 2026 — Biofrontera AG (ISIN: DE000A4BGGM7), an international biopharmaceutical company speci…
Biofrontera AGby Investor RelationsBusiness news for the stock market Leverkusen (pta/30.09.2026/13:30) - Leverkusen, September 30, 2026 — Biofrontera AG (ISIN: DE000A4BGGM7), an international biopharmaceutical company specialized in dermatology, today announced its financial results for the first…
On Thursday, Biofrontera (NASDAQ: BFRI ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit Access the full call at Summary Biofrontera Inc. reported a 33% increase in net produ